University of Hertfordshire

  • Jia Liu
  • Gerta Cami-Kobeci
  • Yiting Wang
  • Pissared Khuituan
  • Zhiwei Cai
  • Hongyu Li
  • Stephen M. Husbands
  • David N. Sheppard
View graph of relations
Original languageEnglish
Title of host publicationIon Channel Drug Discovery
EditorsBrian Cox, Martin Gosling
Place of PublicationCambridge
PublisherRoyal Society of Chemistry
Chapter8
Pages156-185
Number of pages29
Volume2015-January
Edition39
ISBN (Electronic)978-1-84973-508-7
ISBN (Print)978-1-84973-186-7
DOIs
Publication statusPublished - 18 Sep 2014

Publication series

NameRSC Drug Discovery Series
ISSN (Print)2041-3203

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) plays a pivotal role in fluid and electrolyte movements across ducts and tubes lined by epithelia. Loss of CFTR function causes the common life-limiting genetic disease cystic fibrosis (CF) and a spectrum of disorders termed CFTR-related diseases, while unphysiological CFTR activity characterises secretory diarrhoea and autosomal dominant polycystic kidney disease (ADPKD). The prevalence of these disorders argues persuasively that small-molecule CFTR modulators have significant therapeutic potential. Here, we discuss how knowledge and understanding of the CFTR Cl− channel, its physiological role and malfunction in disease led to the development of the CFTR potentiator ivacaftor, the first small molecule targeting CFTR approved as a treatment for CF. We consider the prospects for developing other therapeutics targeting directly CFTR including CFTR correctors to rescue the apical membrane expression of CF mutants, CFTR corrector-potentiators, dual-acting small-molecules to correct the processing and gating defects of F508del-CFTR, the commonest CF mutant and CFTR inhibitors to prevent fluid and electrolyte loss in secretory diarrhoea and cyst swelling in ADPKD. The success of ivacaftor provides impetus to other CFTR drug development programmes and a paradigm for the creation of therapeutics targeting the root cause of other genetic disorders

Notes

© Royal Society of Chemistry 2014

ID: 16775108